



Attorney Docket: 27099U  
Date: April 13, 2006

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

VENNEMANN, et al.

Art Unit: 1614

Examiner: Unknown

Appl. No.: 10/562,149✓

Filed: December 23, 2005

For: **NOVEL PYRROLODIHYDROISOQUINOLINES USEFUL IN THE TREATMENT OF  
CANCER**

**TRANSMITTAL LETTER**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Sir:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

- 1) Information Disclosure Statement;
- 2) PTO Form-1449 with 18 cited References, with copies for 17 of the 18 cited References.

The Commissioner is hereby authorized to charge any deficiency or credit any excess to Deposit Account No. 14-0112.

Respectfully submitted,  
**NATH & ASSOCIATES PLLC**

  
Gary M. Nath, Reg. No. 26,965  
Sheldon M. McGee, Reg. No. 50,454  
Customer No. 34375

NATH & ASSOCIATES PLLC  
112 South West Street  
Alexandria, VA 22314

GMN/SMM/le



Attorney Docket: 27099U

Date: April 13, 2006

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Art Unit: 1614

VENNEMANN, et al.

Examiner: Unknown

Appl. No.: 10/562,149

Filed: December 23, 2005

For: **NOVEL PYRROLODIHYDROISOQUINOLINES USEFUL IN THE TREATMENT OF CANCER**

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. 1.97-1.98. Please note the following particulars: [NOTE: One only of items a, b, c, and d must be checked.]

[XXX] a. The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.

[ ] b. The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311.

The enclosed statement is accompanied by [check one]:

[ ] i. a certification in part (e) below as specified in 37 C.F.R. 1.97(e), or

[ ] ii. a check in the amount required by 37 C.F.R. 1.17(p).

[ ] c. The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. 1.113,

or a notice of allowance under 37 C.F.R. 1.311, but before payment of the issue fee.

☐ Certification report(e) below; and

☐ a check in the amount as required by 1.17(p).

☐ d. The enclosed statement is being filed pursuant to 37 C.F.R. 1.97(i), for placement in the file.

☐ e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]

☐ I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,

or

☐ I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

or

☐ Appropriate certification is attached.

[XXX] f. If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.

[XXX] g. Copies of the documents are attached herewith with a completed Form PTO-1449.

or

[ ] Copies of the documents are not attached as allowed under CFR 1.98(d)(1)(2). The earlier application is identified as:


and / or

[XXX] Copies of US Patents/Publications not attached as allowed in Official Gazette Aug. 5, 2003/ Vol. 1273, no. 1.

The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,  
**NATH & ASSOCIATES PLLC**

  
\_\_\_\_\_  
Gary M. Nath, Reg. No. 26,965  
Sheldon M. McGee, Reg. No. 50,454  
Customer No. 34375

NATH & ASSOCIATES PLLC  
112 South West Street  
Alexandria, VA 22314

GMN/SMM/le

<b>FORM PTO-1449</b> <b>INFORMATION DISCLOSURE CITATION</b>	In re Application of: VENNEMANN, et al.		Art Unit: 1614
	Appl. No: 10/562,149	Filed: December 23, 2005	Examiner: Unknown

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Issue / Publication Date	Inventor	Filed
A1	5,965,575	12 Oct. 1999	Peglion et al.	27 Mar. 1998
A2				
A3				
A4				

## FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Publication Date	Country	Translation
A5	97/28131 A1	7 Aug. 1997	WO	Abstract
A6	98/55118 A2	10 Dec. 1998	WO	N/A
A7	02/48144 A1	20 Jun. 2002	WO	N/A
A8	03/014115 A1	20 Feb. 2003	WO	N/A
A9	03/014116 A1	20 Feb. 2003	WO	N/A

## OTHER

Examiner Initial	(Including Author, Title, Date, Pertinent Pages, etc.)
A10	Ashton, M.J., et al., "Selective Type IV Phosphodiesterase Inhibitors as Antiasthmatic Agents. The Syntheses and Biological Activities of 3-(Cyclopentyloxy)-4-methoxybenzamides and Analogues", <u>J. Med. Chem.</u> , vol. 37, pp. 1696-1703, (1994).
A11	Benovsky, P., et al., "Aza-Annulation as a Versatile Approach to the Synthesis of Non-Benzodiazepene Compounds for the Treatment of Sleep Disorders", <u>Tetrahedron Letters</u> , vol. 38, no. 49, pp. 8475-8478, (1997).
A12	Díaz, M., et al., "Syntheses of Lamellarins I and K by [3+2] Cycloaddition of a Nitron to an Alkyne", <u>Synlett</u> , no. 7, pp. 1164-1166, (2001).
A13	Govindachari, T.R., et al., "Application of the Bruckner Method to the Synthesis of Phenanthridine Derivatives", <u>J. Chem. Soc.</u> , pp. 4280-4283, (1956).
A14	Hershenson, F.M., "Synthesis of Ring-Fused Pyrroles. II. 1,3-Dipolar Cycloaddition Reactions of Munchnone Derivatives Obtained from Tetrahydroisoquinoline-1-carboxylic Acids", <u>J. Org. Chem.</u> , vol. 40, no. 6, (1975).
A15	Meyer, H., "Pyrrole durch cyclisierende Michael-Addition von Enaminen", <u>Liebigs Ann. Chem.</u> , pp. 1534-1544, (1981). (ABSTRACT)

Examiner	Date Considered
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP ' 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<b>FORM PTO-1449</b>  <b><u>INFORMATION DISCLOSURE CITATION</u></b>		In re Application of: VENNEMANN, et al. Appl. No: 10/562,149		Art Unit: 1614 Filed: December 23, 2005 Appl. No: 10/562,149	
<b>U.S. PATENT DOCUMENTS</b>					
Examiner Initial		Document Number	Issue / Publication Date	Inventor	Filed
	A16				
<b>FOREIGN PATENT DOCUMENTS</b>					
Examiner Initial		Document Number	Publication Date	Country	Translation
	A17	03/014117 A1	20 Feb. 2003	WO	N/A
	A18	03/051877 A1	26 Jun. 2003	WO	N/A
	A19	03/093499 A2	13 Nov. 2003	WO	N/A
	A20	2005/002579 A1	13 Jan. 2005	WO	N/A
	A21	2005/003129 A1	13 Jan. 2005	WO	N/A
	A22				
	A23				
	A24				
<b>OTHER</b>					
Examiner Initial		(Including Author, Title, Date, Pertinent Pages, etc.)			
	A25	Shepard, E.R., et al., "Preparation of Some Analogs of Papaverine", <u>J. Org. Chem.</u> , vol. 17, pp. 568-576, (1952).			
	A26				
	A27				
	A28				
	A29				
	A30				
Examiner			Date Considered		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP ' 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.					